argenx SE (NASDAQ:ARGX) Shares Bought by Marshall Wace LLP

Marshall Wace LLP lifted its holdings in argenx SE (NASDAQ:ARGX - Free Report) by 184.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 191,553 shares of the company's stock after acquiring an additional 124,271 shares during the period. Marshall Wace LLP owned approximately 0.32% of argenx worth $117,805,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. United Capital Financial Advisors LLC purchased a new position in argenx in the fourth quarter valued at about $272,000. Mariner LLC lifted its position in argenx by 15.9% during the 4th quarter. Mariner LLC now owns 3,711 shares of the company's stock worth $2,283,000 after acquiring an additional 509 shares in the last quarter. Neuberger Berman Group LLC boosted its holdings in argenx by 9.5% in the 4th quarter. Neuberger Berman Group LLC now owns 770 shares of the company's stock worth $474,000 after acquiring an additional 67 shares during the period. DRW Securities LLC acquired a new stake in argenx in the fourth quarter valued at approximately $780,000. Finally, Raymond James Financial Inc. acquired a new position in shares of argenx during the fourth quarter worth $43,543,000. Hedge funds and other institutional investors own 60.32% of the company's stock.

Wall Street Analysts Forecast Growth

ARGX has been the topic of several analyst reports. Truist Financial reaffirmed a "buy" rating and set a $700.00 price target (up previously from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Deutsche Bank Aktiengesellschaft upgraded argenx from a "sell" rating to a "hold" rating in a research note on Wednesday, March 12th. HC Wainwright reaffirmed a "buy" rating and issued a $720.00 target price on shares of argenx in a research report on Tuesday, April 8th. William Blair reissued an "outperform" rating on shares of argenx in a research report on Friday, February 28th. Finally, Wedbush restated an "outperform" rating and issued a $715.00 price target on shares of argenx in a research note on Friday, April 11th. Three research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $699.28.

argenx Price Performance

Shares of ARGX stock traded up $2.82 during trading hours on Tuesday, reaching $598.52. The stock had a trading volume of 108,669 shares, compared to its average volume of 308,241. The firm has a market capitalization of $36.37 billion, a PE ratio of -680.09 and a beta of 0.60. The firm has a 50-day simple moving average of $601.46 and a 200-day simple moving average of $606.83. argenx SE has a twelve month low of $352.77 and a twelve month high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $761.22 million for the quarter, compared to analysts' expectations of $678.52 million. On average, equities analysts anticipate that argenx SE will post 3.13 earnings per share for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.